Overview

This trial is active, not recruiting.

Condition non-small cell lung cancer, metastatic colorectal cancer, metastatic non small cell lung cancer, metastatic cancers, melanoma
Treatments cobimetinib, gd0-994
Phase phase 1
Targets MEK, ERK
Sponsor Genentech, Inc.
Start date June 2015
End date September 2018
Trial size 27 participants
Trial identifier NCT02457793, 2015-000092-27, GO29653

Summary

This is a two-stage dose-escalation study to assess the safety, tolerability and effects of oral dosing of cobimetinib and GDC-0994 administered in combination in patients with histologically confirmed, locally advanced, or metastatic solid tumors for which standard therapies either do not exist or have proven ineffective or intolerable.

United States Connecticut
Other Countries No locations recruiting

Study Design

Allocation non-randomized
Endpoint classification safety study
Intervention model crossover assignment
Masking open label
Primary purpose treatment
Arm
(Experimental)
Concurrent cobimetinib and GDC-0994
cobimetinib
gd0-994
(Experimental)
Intermittent dosing of cobimetinib concurrent with GDC-0994
cobimetinib
gd0-994
(Experimental)
Cobimetinib in combination with GDC-0994
cobimetinib
gd0-994

Primary Outcomes

Measure
Percentage of patients with dose limiting toxicity (DLTs)
time frame: Up to 3 years
Percentage of patients experiencing at least one adverse event
time frame: Up to 3 years
Mean change from baseline in vital signs
time frame: Up to 3 years
Percentage of patients with at least one adverse event of special interest
time frame: Up to 3 years
Percentage of patients experiencing at least one serious adverse event
time frame: Up to 3 years
Percentage of patients experiencing laboratory abnormalities
time frame: Up to 3 years

Secondary Outcomes

Measure
Mean accumulation ratio
time frame: Up to 3 years
Pharmacokinetic: Serum concentration (Cmax)
time frame: Up to day 22 of study
Pharmacokinetic: Total exposure (AUC from time 0 to 24 hour after dose)
time frame: Up to day 22 of study
Pharmacokinetic: Median time to maximum concentration (t-max)
time frame: Up to day 22 of study
Pharmacokinetic: Mean terminal half-life (t1/2)
time frame: Up to day 22 of study
Pharmacodynamic: Change from baseline in fluorodeoxyglucose positron emission tomography (FDG-PET)
time frame: Day 15 of study
Pharmacodynamic: Change from baseline in tumor tissue biomarkers
time frame: Up to 3 years
Objective Response (OR) for patients with measurable disease
time frame: Up to 3 years
Progression-Free Survival (PFS)
time frame: Up to 3 years
Duration of Response (DOR)
time frame: Up to 3 years

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 - Histologically or cytologically documented, locally advanced or metastatic solid tumors for which standard therapy either does not exist or has proven ineffective or intolerable - Evaluable disease or disease measurable - Life expectancy > or = 12 weeks - Adequate hematologic and end organ function - For female patients of childbearing potential and male patients with partners of childbearing potential, use of an effective form of contraception with continued use for study duration and up to 3 months or more following discontinuation of treatment drug - Fluorodeoxyglucose positron emission tomography (FDG-PET) avid disease on baseline scan For enrollment in part 2, patients must meet all of the following: - Measurable disease - No more than four prior systemic therapies for locally advanced or metastatic cancer Exclusion Criteria: - History of prior significant toxicity from another MEK inhibitor or ERK inhibitor requiring discontinuation of treatment - Evidence of visible retinal pathology as assessed by ophthalmologic examination that is considered a risk factor for retinal vein thrombosis - History of glaucoma - Intraocular pressure > 21 mmHg as measured by tonometry - Predisposing factors to retinal vein occlusion (RVO) - History of RVO, neurosensory retinal detachment, or neovascular macular degeneration - Allergy or hypersensitivity to components of the cobimetinib or GDC-0994 formulation - Palliative radiotherapy within 2 weeks prior to first dose of study-drug treatment in Cycle 1 - Experimental therapy within 4 weeks prior to first dose of study-drug treatment in Cycle 1 - Major surgical procedure or significant traumatic injury within 4 weeks prior to the first dose of study-drug treatment in Cycle 1, or anticipation of the need for major surgery during the course of study treatment - Anti-cancer therapy within 28 days prior to the first dose of study-drug treatment in Cycle 1 - Current severe, uncontrolled systemic disease - History of clinically significant cardiac dysfunction - History of symptomatic congestive heart failure or serious cardiac arrhythmia requiring treatment - History of myocardial infarction within 6 months prior to the first dose of study-drug treatment in Cycle 1 - History of congenital long QT syndrome or QTc > 470 msec - LVEF - History of malabsorption or other condition that would interfere with enteral absorption - Clinically significant history of liver disease, current alcohol abuse, or current known active infection with HIV, hepatitis B virus, or hepatitis C virus - Any condition requiring warfarin or thrombolytic anticoagulants - Active autoimmune disease - Uncontrolled ascites requiring weekly large volume paracentesis for 3 consecutive weeks prior to enrollment - Pregnancy, lactation, or breastfeeding - Known brain metastases that are untreated, symptomatic, or require therapy to control symptoms - No other history of or ongoing malignancy that would potentially interfere with the interpretation of the Pharmacodynamic (PD) or efficacy assays

Additional Information

Official title A Phase Ib, Open-Label, Dose-Escalation Study Of The Safety, Tolerability, and Pharmacokinetics of Cobimetinib and GDC-0994 In Patients With Locally Advanced or Metastatic Solid Tumors
Trial information was received from ClinicalTrials.gov and was last updated in November 2016.
Information provided to ClinicalTrials.gov by Genentech, Inc..